Experimental and theoretical study demonstrates altered mutagenicity and lethality of norfloxacin analogues in aquatic and rodent models, highlighting structural drivers of drug biotoxicity.
To clarify the effect of the fluorine atom and piperazine ring on norfloxacin (NOR), NOR degradation products (NOR-DPs, P1–P8) were generated via UV combined with hydrogen peroxide (UV/H2O2) technology. NOR degradation did not significantly affect cytotoxicity of NOR against BV2, A549, HepG2, and Vero E6 cells. Compared with that of NOR, mutagenicity and median lethal concentration of P1–P8 in fathead minnow were increased, and bioaccumulation factor and oral median lethal dose of P1–P8 in rats were decreased. Molecular docking was used to evaluate the inhibitory effect of DNA gyrase A (gyrA) on NOR-DPs to determine the molecular-level mechanism and establish the structure–activity relationship. Results indicated that the most common amino acid residues were Ile13, Ser27, Val28, Gly31, Asp36, Arg46, Arg47, Asp157, and Gly340; hydrogen bonds and hydrophobic interactions played key roles in the inhibitory effect. Binding area (BA) decreased from 350.80 Å2 (NOR) to 346.21 Å2 (P1), and the absolute value of binding energy (|BE|) changed from 2.53 kcal/mol (NOR) to 2.54 kcal/mol (P1), indicating that the fluorine atom mainly affects BA. The piperazine ring clearly influenced BA and |BE|. "Yang ChuanXi Rules" were used to explain effects of molecular weight (MW), BA, |BE|, and sum of η1 + η2 (η1: normalization of BA, η2: normalization of |BE|) and predict biotoxicity of NOR-DPs based on half-maximum inhibitory concentration (IC50), half-minimal inhibitory concentration (MIC50), and half-minimal bactericidal concentration (MBC50) values.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: